fluorouracil has been researched along with phosphorylcholine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J | 1 |
| Alfieri, AA; Koutcher, JA; Street, JC; Traganos, F | 1 |
| Ishihara, K; Kimura, M; Takai, M | 1 |
| Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ | 1 |
| Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG | 1 |
| He, N; Lv, Z; Wang, S; Zhao, W | 1 |
| Imano, M; Morii, Y; Nishida, S; Otubo, R; Satou, T; Seki, S; Shimomura, K; Takeda, T; Tsubaki, M; Yamatomo, Y | 1 |
1 trial(s) available for fluorouracil and phosphorylcholine
| Article | Year |
|---|---|
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Phosphorylcholine | 2011 |
6 other study(ies) available for fluorouracil and phosphorylcholine
| Article | Year |
|---|---|
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Humans; Male; Phosphorylcholine; Prostatic Neoplasms; Suramin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1994 |
In vivo and ex vivo study of metabolic and cellular effects of 5-fluorouracil chemotherapy in a mouse mammary carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Cycle; Ethanolamines; Fluorouracil; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Phosphorylcholine; Tissue Extracts | 1997 |
Biocompatibility and drug release behavior of spontaneously formed phospholipid polymer hydrogels.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Antimetabolites; Biocompatible Materials; Delayed-Action Preparations; Doxorubicin; Fluorouracil; Humans; Hydrogels; Indomethacin; Ketoprofen; Male; Materials Testing; Methacrylates; Phosphorylcholine; Rats; Rats, Sprague-Dawley | 2007 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
MicroRNA analysis of NCI-60 human cancer cells indicates that miR-720 and miR-887 are potential therapeutic biomarkers for breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Databases, Genetic; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Phosphorylcholine; Survival Analysis; Up-Regulation | 2020 |
Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caco-2 Cells; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Mutation; Oxaliplatin; Phosphorylation; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction | 2021 |